Annual Report 2015 Active Biotech AB (publ)
April 29 2016 - 4:06AM
Active Biotech's Annual Report 2015 is now available for
download at www.activebiotech.com.
The Annual Report will only be digitally distributed. The
English version will be available within short.
LUND, Sweden, April 29, 2016 (GLOBE NEWSWIRE) --
Active Biotech AB (publ) Tomas Leanderson President &
CEO
For further information, please contact: Hans
Kolam, CFO Tel +46 (0)46 19 20 44
Active Biotech AB (publ) (Nasdaq Stockholm:
ACTI) is a biotechnology company with focus on
neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory
properties, is in pivotal Phase 3 development for the treatment of
relapsing remitting multiple sclerosis. Also, laquinimod is in
Phase 2 development for the treatment of primary progressive
multiple sclerosis and Huntington's disease. Furthermore,
commercial activities are conducted for the tasquinimod, SILC,
ANYARA and paquinimod projects. Please visit www.activebiotech.com
for more information.
Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220
07 Lund, Sweden Tel: +46 (0)46 19 20 00 Fax: +46 (0)46 19 11 05
Active Biotech is obligated to publish the
information contained in this press release in accordance with the
Swedish Securities Market Act and/or the Financial Instruments
Trading Act. This information was provided to the media for
publication on April 29, 2016 at 10:00 a.m.
Annual Report 2015 Active Biotech AB (publ)
http://hugin.info/1002/R/2007443/742090.pdf
HUG#2007443
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024
